Business context and reporting period
This is Celsion Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2013, filed August 8, 2013. The filing identifies the registrant as Celsion Corporation, not Imunon, Inc. Celsion was a clinical-stage oncology company developing ThermoDox, a heat-activated liposomal drug candidate. It reported no product sales; revenue was licensing-related.
Key financial metrics
| Metric | Three months ended June 30, 2013 | Six months ended June 30, 2013 | Comparable 2012 period |
|---|---|---|---|
| Licensing revenue | $125,000 | $250,000 | $0 |
| Research and development expense | $2.02 million | $5.23 million | $4.11 million / $8.81 million |
| General and administrative expense | $1.95 million | $3.64 million | $1.60 million / $3.17 million |
| Net income (loss) | $420,884 | $(230,090) | $(6.10 million) / $(12.29 million) |
| Net income (loss) attributable to common shareholders | $420,884 | $(4.83 million) | $(6.10 million) / $(12.29 million) |
| Net cash used in operating activities | Not presented for the quarter | $3.59 million | $10.91 million |
At June 30, cash and cash equivalents were $6.02 million and available-for-sale investments were $42.71 million; including accrued interest, cash and short-term investments totaled approximately $48.9 million. Working capital was $43.9 million. Total assets were $51.0 million, total liabilities $18.0 million, and stockholders’ equity $33.0 million. Notes payable totaled $4.75 million, including current and non-current portions; the secured term loan carried a fixed 11.75% interest rate and was due to mature October 15, 2015. The company said it was in compliance with loan covenants.
Six-month investing cash outflow was $34.76 million, primarily reflecting purchases of investment securities. Financing provided $29.38 million, including proceeds from equity and preferred-stock offerings. The filing does not provide a revenue-based operating margin meaningful for this pre-commercial company.
Material changes versus the prior comparable period
- Second-quarter operating expenses fell 30% year over year, and six-month operating expenses fell 26%, largely as clinical-trial and manufacturing costs declined following the HEAT study result. R&D expense decreased 50% in Q2 and 41% for the six-month period.
- G&A expense rose 22% in Q2 and 15% over six months; Q2 included a one-time $0.3 million severance charge.
- Reported earnings benefited substantially from a non-cash gain on the fair value of warrant liabilities: $4.38 million in Q2 and $8.66 million for the first half. Excluding this item, reported net income should not be interpreted as evidence of operating profitability.
- Six-month loss attributable to common shareholders included a $4.60 million non-cash deemed dividend from the beneficial conversion feature of preferred stock.
- The company raised capital through an ATM offering, a February preferred-stock offering and a June common-stock offering. All Series A 0% preferred shares from the February offering had converted into common shares by June 30. Common shares outstanding increased to 61.16 million from 37.30 million at year-end 2012.
Outlook, management commentary, risks and unusual items
- ThermoDox combined with radiofrequency ablation failed to meet the primary endpoint of the Phase III HEAT study, announced January 31, 2013. The company continued follow-up for overall survival and further analysis. Management described post hoc findings suggesting benefit in a subgroup receiving at least 45 minutes of ablation, but said these findings required further verification and review.
- The company deferred expenses for its Phase II ABLATE study in colorectal liver metastases pending decisions on ThermoDox’s development. It also reported a Phase II study in recurrent chest-wall breast cancer.
- An April restructuring eliminated approximately one-third of the workforce. Management expected G&A costs to decline during the remainder of 2013. It warned that substantial additional capital would be needed and that it had no committed financing sources; further equity financing could dilute shareholders.
- Hisun paid a non-refundable $5.0 million development fee in January, recorded as deferred revenue and recognized over the 10-year agreement. A July 19, 2013 memorandum of understanding contemplated continued collaboration, non-dilutive financing for specified China-related work, and a right of first offer for a China commercial license; the filing does not establish that all contemplated arrangements were finalized.
- On June 3, 2013, $9.1 million of warrants were reclassified from equity to liabilities because authorized shares were insufficient to satisfy them. Subsequent fair-value changes ran through earnings, creating potentially volatile non-cash results. Stockholders later approved board authority to effect a reverse split and set authorized shares, subject to the terms described in the filing.
- The company was reassessing accounting for its January 2011 preferred offering after a draft PCAOB report indicated that the accounting may have been improper. Celsion disputed that view and said any necessary adjustment or restatement was expected to be non-cash and isolated to 2011, but a restatement could still have consequences.
- Management stated disclosure controls were effective at a reasonable-assurance level and reported no material change in internal controls over financial reporting. The filing reported no legal proceedings and no off-balance-sheet financing arrangements.
- Principal risks include clinical and regulatory failure, limited revenue, continued operating losses, need for additional capital, dilution, dependence on partners and third-party trial operators, competition, stock-price volatility and potential Nasdaq listing compliance issues.
Important facts for investors to verify
- Confirm the issuer and period: the supplied filing is Celsion Corporation’s 2013 Q2 10-Q, despite the request metadata naming Imunon, Inc.
- Review the HEAT study’s final overall-survival results and validation of the post hoc subgroup analysis before assigning value to ThermoDox.
- Assess cash use and financing needs against the company’s clinical plans; the filing provides no definitive cash runway estimate.
- Track warrant liability valuation and its non-cash effect on earnings, as well as potential dilution from warrants, options and future offerings.
- Follow the accounting review of the 2011 preferred offering for any required adjustment, reclassification or restatement.
- Check the status and binding terms of the Hisun collaboration, contemplated financing and China development activities.